表紙
市場調查報告書

胞外體技術:主要企業的R&D最新趨勢 - Capricor Therapeutics、Codiak Biosciences、Evox Therapeutics

Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players

出版商 GlobalData 商品編碼 747505
出版日期 內容資訊 英文 93 Pages
訂單完成後即時交付
價格
Back to Top
胞外體技術:主要企業的R&D最新趨勢 - Capricor Therapeutics、Codiak Biosciences、Evox Therapeutics Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players
出版日期: 2018年10月12日內容資訊: 英文 93 Pages
簡介

本報告提供胞外體的多樣的醫療保健用途相關詳細資訊,開發平台,臨床試驗,及企業形勢評價。

第1章 目錄

第2章 醫療保健的胞外體

  • 胞外體概要
  • 藥物遞輸系統
  • 胞外體的生命週期
  • 生物學的胞外體
  • 醫藥的胞外體
  • 治療標的的胞外體
  • 藥物輸送載波的胞外體
  • 治療用胞外體的調整
  • 治療藥碾子究的胞外體
  • 癌症的胞外體
  • CNS疾病的胞外體
  • 其他疾病的胞外體

第3章 開發中產品革新的評估

  • 概要
  • 胞外體開發平台:各開發階段、分子類型
  • 開發平台:各分子標的
  • 開發平台:各治療領域、適應症
  • 開發中產品的簡介

第4章 臨床試驗形勢的評估

  • 介入臨床試驗
  • 觀察臨床試驗

第5章 企業分析、定位

  • 企業簡介
    • Capricor Therapeutics Inc.
    • Evox Therapeutics Ltd
    • ReNeuron Group Plc
    • Stem Cell Medicine Ltd
    • Tavec Inc.
    • Codiak Biosciences Inc.
    • Therapeutic Solutions International Inc.
    • ArunA Biomedical Inc.
    • Ciloa

第6章 附錄

目錄
Product Code: GBI092CBR

Summary

Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine, cerebrospinal fluid (CSF) as well as in in vitro cell culture. These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right.

Exosome can be engineered to incorporate targeting ligands, allowing them to deliver cargo selectively to cells. Their small size allows them to penetrate the blood-brain barrier (BBB) for the delivery of central nervous system (CNS) therapies, whereas in cancer they can accumulate within the tumor via enhanced permeability and retention effects. Research within this area remains in the nascent stages, though several clinical studies have been registered within the field.

Although research within the exosome field is in the early stages, the area boasts a broad and diverse pipeline consisting of 22 active products. The majority of these products are within the Preclinical stage of development, and are indicated for the treatment of cancer. Other therapeutic areas strongly represented in this pipeline include the CNS and cardiovascular therapy areas. The clinical trials landscape for exosome therapies is similarly diverse. Since 2006, a total of 124 clinical trials have taken place.

As a result, interest and investment within the field of exosome therapies have been increasing steadily over the past 10 years. Currently there is only one product approved for use on the market, the Exodx Prostate Intelliscore diagnostic test for prostate cancer, developed and marketed by Exosome Diagnostics.

There are a range of companies within the pipeline landscape, most of which have only become established within the past few years. One of the leading companies in this sector is Capricor Therapeutics. The company is forecast to make a profit on the market with a net revenue of $333 million forecast for 2024 attributable to the anticipated successful development of its key product CAP-1002.

"Exosome Technologies: Recent Surge in R&D with Capricor, Codiak and Evox Therapeutics among Key Players", explores the application of Exosome technologies within the pharmaceutical and healthcare industries.

This report provides detailed information on the various healthcare applications of exosomes, and assesses the pipeline, clinical trial and company landscapes.

Scope

  • What are the features of the exosome lifecycle?
  • How are therapeutic exosomes prepared?
  • How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area?
  • Which companies are investing in exosome technologies?
  • How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors?

Reasons to buy

  • Develop a comprehensive understanding of exosome technologies and their potential for use within the healthcare sector.
  • Analyze the pipeline landscape and gain insight into the key companies investing in exosomes technologies.
  • Identify trends in interventional and observational clinical trials relevant to exosomes.

Table of Contents

1 Table of Contents

  • 1 Table of Contents 4
  • 1.1 List of Tables 6
  • 1.2 List of Figures 7

2 Exosomes in Healthcare 8

  • 2.1 Overview of Exosomes 8
  • 2.2 Drug Delivery Systems 9
    • 2.2.1 Modified Release Drug Delivery Systems 9
    • 2.2.2 Targeted Drug Delivery Systems 10
    • 2.2.3 Liposomes 12
    • 2.2.4 Viruses 14
    • 2.2.5 Exosomes 17
  • 2.3 The Exosome Lifecycle 18
  • 2.4 Exosomes in Biology 18
  • 2.5 Exosomes in Medicine 19
    • 2.5.1 Biomarkers 19
    • 2.5.2 Vaccines 20
  • 2.6 Exosomes as a Therapeutic Target 20
  • 2.7 Exosomes as Drug Delivery Vehicles 21
  • 2.8 Therapeutic Preparation of Exosomes 21
    • 2.8.1 Isolation and Purification 22
    • 2.8.2 Drug Loading 22
    • 2.8.3 Characterization 23
    • 2.8.4 Bioengineering 23
    • 2.8.5 Biodistribution and In Vivo Studies 23
    • 2.8.6 Advantages of Exosome Therapies 24
    • 2.8.7 Disadvantages of Exosome Therapies 24
  • 2.9 Exosomes in Therapeutic Research 25
    • 2.9.1 Exosome Gene Therapies 25
    • 2.9.2 Exosome in Stem Cell Therapy 26
  • 2.10 Exosomes in Oncology 27
    • 2.10.1 Immunotherapy 27
    • 2.10.2 Gene Therapy 28
    • 2.10.3 Drug Delivery 29
    • 2.10.4 Biomarkers 30
  • 2.11 Exosomes in CNS Disease 30
    • 2.11.1 Tackling the Blood-Brain Barrier 30
    • 2.11.2 Exosomes in CNS Drug Delivery 31
    • 2.11.3 Gene Therapy 32
  • 2.12 Exosomes in Other Diseases 33
    • 2.12.1 Cardiovascular Disease 33
    • 2.12.2 Metabolic Disease 33

3 Assessment of Pipeline Product Innovation 36

  • 3.1 Overview 36
  • 3.2 Exosome Pipeline by Stage of Development and Molecule Type 36
  • 3.3 Pipeline by Molecular Target 37
  • 3.4 Pipeline by Therapy Area and Indication 38
  • 3.5 Pipeline Product Profiles 38
    • 3.5.1 AB-126 - ArunA Biomedical Inc. 38
    • 3.5.2 ALX-029 and ALX-102 - Alxerion Biotech 39
    • 3.5.3 Biologics for Autism - Stem Cell Medicine Ltd 39
    • 3.5.4 Biologic for Breast Cancer - Exovita Biosciences Inc. 39
    • 3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis - Regenasome Pty 39
    • 3.5.6 Biologic for Lysosomal Storage Disorder - Exerkine 39
    • 3.5.7 Biologics for Prostate Cancer - Cells for Cells 40
    • 3.5.8 CAP-2003 - Capricor Therapeutics Inc. 40
    • 3.5.9 CAP-1002 - Capricor Therapeutics Inc. 41
    • 3.5.10 CIL-15001 and CIL-15002 - Ciloa 42
    • 3.5.11 ExoPr0 - ReNeuron Group Plc 42
    • 3.5.12 MVAX-001 - MolecuVax Inc. 43
    • 3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke - Isfahan University of Medical Sciences 44
    • 3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer - Codiak BioSciences Inc. 44
    • 3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology - Evox Therapeutics Ltd 44
    • 3.5.16 TVC-201 and TVC-300 - Tavec Inc. 45

4 Assessment of Clinical Trial Landscape 48

  • 4.1 Interventional Clinical Trials 48
    • 4.1.1 Clinical Trials by Therapy Type 48
    • 4.1.2 Clinical Trials by Therapy Area 49
    • 4.1.3 Clinical Trials by Stage of Development 50
    • 4.1.4 Clinical Trials by Start Date and Status 50
  • 4.2 Observational Clinical Trials 51
    • 4.2.1 Clinical Trials by Therapy Type 51
    • 4.2.2 Clinical Trials by Therapy Area 51
    • 4.2.3 Clinical Trials by Stage of Development 52
    • 4.2.4 Clinical Trials by Start Date and Status 53
    • 4.2.5 List of All Clinical Trials 54

5 Company Analysis and Positioning 67

  • 5.1 Company Profiles 67
    • 5.1.1 Capricor Therapeutics Inc. 67
    • 5.1.2 Evox Therapeutics Ltd 72
    • 5.1.3 ReNeuron Group Plc 73
    • 5.1.4 Stem Cell Medicine Ltd 77
    • 5.1.5 Tavec Inc. 78
    • 5.1.6 Codiak Biosciences Inc. 80
    • 5.1.7 Therapeutic Solutions International Inc. 81
    • 5.1.8 ArunA Biomedical Inc. 83
    • 5.1.9 Ciloa 85

6 Appendix 86

  • 6.1 References 86
  • 6.2 Abbreviations 91
  • 6.3 About GBI Research 93
  • 6.4 Disclaimer 93

List of Tables

  • Table 1: Exosome Technologies, Global, Examples of Modified Release Dosage Systems, 2018 10
  • Table 2: Exosome Technologies, Global, Challenges and Opportunities in Drug Delivery, 2018 11
  • Table 3: Exosome Technologies, Global, Breakdown of Lipid-Based Drug Delivery Systems, 2018 13
  • Table 4: Exosome Technologies, Global, Types of Viral Vector for Gene Therapy Delivery, 2018 15
  • Table 5: Exosome Technologies, Global, Capricor Pipeline Products, 2018 69
  • Table 6: Exosome Technologies, Global, Capricor Clinical Trials, 2018 70
  • Table 7: Exosome Technologies, Global, Capricor Completed Deals, 2009-2018 72
  • Table 8: Exosome Technologies, Global, Evox Pipeline Products, 2018 73
  • Table 9: Exosome Technologies, Global, Evox, Completed Deals, 2018 73
  • Table 10: Exosome Technologies, Global, ReNeuron Pipeline Products, 2018 75
  • Table 11: Exosome Technologies, Global, ReNeuron Clinical Trials, 2010-2019 75
  • Table 12: Exosome Technologies, Global, ReNeuron Completed Deals, 2018 76
  • Table 13: Exosome Technologies, Global, Stem Cell Medicine Pipeline Products, 2018 78
  • Table 14: Exosome Technologies, Global, Stem Cell Medicine Completed Deals, 2018 78
  • Table 15: Exosome Technologies, Global, Tavec Pipeline Products, 2018 79
  • Table 16: Exosome Technologies, Global, Tavec Clinical Trials, 2018 79
  • Table 17: Exosome Technologies, Global, Tavec Completed Deals, 2018 79
  • Table 18: Exosome Technologies, Global, Codiak Biosciences Pipeline Products, 2018 80
  • Table 19: Exosome Technologies, Global, Codiak Biosciences Clinical Trials, 2018 81
  • Table 20: Exosome Technologies, Global, Codiak Biosciences Completed Deals, 2018 81
  • Table 21: Exosome Technologies, Global, Therapeutic Solutions International Pipeline Products, 2018 82
  • Table 22: Exosome Technologies, Global, Therapeutic Solutions International Clinical Trials, 2018 82
  • Table 23: Exosome Technologies, Global, Therapeutic Solutions International Completed Deals, 2018 83
  • Table 24: Exosome Technologies, Global, ArunA Biomedical Pipeline Products, 2018 84
  • Table 25: Exosome Technologies, Global, ArunA Biomedical Clinical Trials, 2018 84
  • Table 26: Exosome Technologies, Global, ArunA Biomedical Completed Deals, 2018 84
  • Table 27: Exosome Technologies, Global, Ciloa Pipeline Products, 2018 85
  • Table 28: Exosome Technologies, Global, Ciloa Completed Deals, 2018 85

List of Figures

  • Figure 1: Exosome Technologies, Global, Pipeline by Stage of Development and Molecule Type, 2018 37
  • Figure 2: Exosome Technologies, Global, Pipeline by Therapy Area, 2018 38
  • Figure 3: Exosome Technologies, Global, List of All Pipeline Programs Involving Exosomes, 2018 (part 1) 46
  • Figure 4: Exosome Technologies, Global, List of All Pipeline Programs Involving Exosomes, 2018 (part 2) 47
  • Figure 5: Exosome Technologies, Global, Clinical Trials by Study Design, 2006-2025 48
  • Figure 6: Exosome Technologies, Global, Interventional Clinical Trials by Therapy Type, 2006-2022 49
  • Figure 7: Exosome Technologies, Global, Interventional Clinical Trials by Therapy Area, 2006-2022 49
  • Figure 8: Exosome Technologies, Global, Interventional Clinical Trials by Stage of Development, 2006-2022 50
  • Figure 9: Exosome Technologies, Global, Interventional Clinical Trials by Year, 2006-2022 51
  • Figure 10: Exosome Technologies, Global, Observational Trials by Therapy Area, 2011-2025 52
  • Figure 11: Exosome Technologies, Global, Observational Trials by Therapy Area, 2011-2025 52
  • Figure 12: Exosome Technologies, Global, Observational Clinical Trials by Year, 2011-2025 53
  • Figure 13: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 1) 54
  • Figure 14: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 2) 55
  • Figure 15: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 3) 56
  • Figure 16: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 4) 57
  • Figure 17: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 5) 58
  • Figure 18: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 6) 59
  • Figure 19: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 7) 60
  • Figure 20: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 8) 61
  • Figure 21: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 9) 62
  • Figure 22: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 10) 63
  • Figure 23: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 11) 64
  • Figure 24: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 12) 65
  • Figure 25: Exosome Technologies, Global, List of All Clinical Trials, 2006-2025 (part 13) 66
  • Figure 26: Exosome Technologies, Global, Company Analysis Matrix, 2018 67
Back to Top